GlassScriptPhysician profile
Saad Ahmad
NPI 1881613297
$37,065.23
in general payments reported to CMS, 2019-2025
34 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $2,363 · 2021: $780 · 2022: $16K · 2023: $2,305 · 2024: $2,850 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,739 · Food and Beverage: $6,920 · Honoraria: $2,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,739.00 |
| Food and Beverage | $6,919.60 |
| Honoraria | $2,965.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $13,139.20 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $7,144.37 | 2019-2025 | Susvimo, Vabysmo |
| Carl Zeiss Meditec USA, INC. | $4,231.88 | 2022 | |
| Astellas Pharma US INC | $2,316.04 | 2023-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $1,889.27 | 2025 | Iluvien, Purified Cortrophin Gel |
| Eyepoint US, INC. | $1,800.19 | 2020-2023 | |
| Apellis Pharmaceuticals, INC. | $1,207.84 | 2023-2025 | Syfovre |
| Abbvie INC. | $984.56 | 2022-2025 | Ozurdex, Xen Glaucoma Treatment System, Vuity |
| Allergan, INC. | $738.27 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $701.37 | 2019-2025 | Eylea Hd, Eylea, Dupixent |
| Alcon Vision LLC | $365.45 | 2022-2025 | Rocklatan, Simbrinza |
| Bausch & Lomb Americas INC. | $343.15 | 2022-2023 | Lotemax Sm, Vyzulta, Stellaris |
| Mallinckrodt Hospital Products INC. | $341.51 | 2020-2025 | Acthar |
| Notal Vision, INC. | $325.54 | 2022 | |
| Glaukos Corporation | $249.32 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $183.41 | 2025 | Iheezo, Triesence, Vevye |
| Dutch Ophthalmic, USA | $171.51 | 2023 | Tissueblue, Eva, Combined Machine |
| Spark Therapeutics, INC. | $151.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $129.26 | 2019-2021 | |
| Ocular Therapeutix, INC. | $120.71 | 2019-2023 | Dextenza |
| Lkc Technologies, INC. | $105.56 | 2025 | |
| Nova Eye, INC. | $76.17 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $68.92 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $46.33 | 2019 | |
| Biotissue Holdings INC. | $42.06 | 2021 | |
| Neurotech Pharmaceuticals, INC. | $41.27 | 2025 | |
| Mallinckrodt Enterprises LLC | $35.67 | 2019 | |
| Astellas Pharma Global Development | $25.97 | 2025 | Izervay |
| New World Medical,INC. | $23.77 | 2019 | |
| Eyevance Pharmaceuticals LLC | $19.49 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $16.46 | 2019 | |
| Genentech, INC. | $15.64 | 2019 | |
| Boston Scientific Corporation | $13.09 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.